Maze Therapeutics Exec Reports $736K Sale as Stock Plunges 33% Amid Positive Phase 2 Data

Maze Therapeutics executive Harold Bernstein reported selling 15,000 shares for $736,000 on March 20, 2026, yielding a transaction value of $49.10 per share. The activity was executed under a Rule 10b5-1 plan, indicating pre-planned liquidity, and did not affect indirect holdings. Bernstein retains options underlying 252,407 shares. Despite the sale, Maze shares crashed 33% on Wednesday following positive Phase 2 data for MZE829.